DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
RAF-265 is an investigational drug.
There have been 225 clinical trials for RAF-265. The most recent clinical trial was a Phase 3 trial, which was initiated on January 1st 2014.
The most common disease conditions in clinical trials are Melanoma, Colorectal Neoplasms, and Carcinoma. The leading clinical trial sponsors are National Cancer Institute (NCI), Bayer, and Novartis Pharmaceuticals.
There are thirty-nine US patents protecting this investigational drug and six hundred and thirty-eight international patents.
Recent Clinical Trials for RAF-265
|Preventative Skin Care for Children Undergoing Targeted CNS Tumor Therapy||Dana-Farber Cancer Institute||Phase 2|
|Neoadjuvant Immunotherapy in Brain Metastases||Bristol-Myers Squibb||Phase 2|
|Neoadjuvant Immunotherapy in Brain Metastases||Duke University||Phase 2|
Top disease conditions for RAF-265
Top clinical trial sponsors for RAF-265
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|RAF-265||Start Trial||Low, immune enhancing, dose mtor inhibitors and uses thereof||Novartis AG (Basel, CH)||Start Trial|
|RAF-265||Start Trial||Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptor||Novartis AG (Basel, CH) The Trustees of the University of Pennsylvania (Philadelphia, PA)||Start Trial|
|RAF-265||Start Trial||Formylated N-heterocyclic derivatives as FGFR4 inhibitors||NOVARTIS AG (Basel, CH)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|